Name | 3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide |
---|---|
Synonyms |
Enalquireno [INN-Spanish]
Enalkirene [INN-French] ENALKIREN Enalkirenum [INN-Latin] Enalquireno L-Histidinamide,N-(3-amino-3-methyl-1-oxobutyl)-O-methyl-L-tyrosyl-N-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-,(1S-(1R*,2S*,3R*)) |
Description | Enalkiren (A-64662) is a potent dipeptide renin inhibitor with an IC50 of 0.78 nM in a purified renal renin-angiotensinogen system (pH=6.0). Enalkiren suppresses renin activity, and also reduces systolic and diastolic blood pressure. Enalkiren can be used to research essential hypertension[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 23 nM (hamster dipeptide renin), 14 nM (human dipeptide renin), 2.3 nM (cynomolgus monkey dipeptide renin)[2] |
In Vitro | Enalkiren inhibits the endogenous renin-angiotensinogen reaction with an IC50 value of 23 nM, 14 nM and 2.3 nM in hamster, human and cynomolgus monkey plasma, respectively, at pH 7.4[2]. |
In Vivo | Enalkiren (0.01-10 mg/kg; i.v.; single dosage) reduces mean arterial blood pressure in cynomolgus monkey[2]. Animal Model: Cynomolgus monkey[2] Dosage: 0.01-10 mg/kg Administration: i.v.; single dosage Result: Reduced mean arterial blood pressure in a dose-related manner. |
Density | 1.172g/cm3 |
---|---|
Boiling Point | 986.3ºC at 760mmHg |
Molecular Formula | C35H56N6O6 |
Molecular Weight | 656.85600 |
Flash Point | 550.3ºC |
Exact Mass | 656.42600 |
PSA | 191.69000 |
LogP | 4.39660 |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.559 |